^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Neuroendocrine Tumor
    Drug:spartalizumab (PDR001) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Endocr Relat Cancer
    Title:

    Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms

    Published date:
    01/01/2021
    Excerpt:
    In this phase II, multicenter, single-arm study, patients received spartalizumab 400 mg every 4 weeks until confirmed disease progression or unacceptable toxicity…The ORR was higher in patients with ≥1% PD-L1 expression in immune/tumor cells or ≥1% CD8+ cells at baseline.
    DOI:
    10.1530/ERC-20-0382